There is an expanding role for bispecific antibodies in the treatment of lung cancer, with amivantamab (EGFR-MET–bispecific antibody) approved for the treatment of advanced EGFR-mutated NSCLC.101. Here, MET is linked to non-small cell lung carcinoma.